Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Dermatologic Complications: later-stage trial registry
A small indexed set (2 trials) with no open enrollment listed right now.
Corpus placement: #7,188 of 28,707 conditions by registered trial count.
2 US clinical trials · none currently recruiting · #7,188 of 28,707 conditions by registered trial count
Dermatologic Complications: 2 US clinical trials tracked, none currently recruiting.
Dermatologic Complications is the subject of 2 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is North Central Cancer Treatment Group, running 1 of these trials.
Enrollment posture brief
Registry condition dermatologic-complications
OPEN 0 | RECR 0% | LATE 1 | EARLY 0 | RANK #7188 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Dermatologic Complications has no open enrollment in this registry pull (2 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Dermatologic Complications on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Dermatologic Complications is recruiting below its size-band peers.
0 of 2 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
2 total, page 1 of 1
Mometasone Furoate in Preventing Radiation Dermatitis in Patients Undergoing Radiation Therapy to the Breast or Chest Wall for Invasive Breast Cancer or Ductal Carcinoma in Situ
North Central Cancer Treatment Group
NCT00438659
S1013: Validation of Cancer Questionnaire for Skin Toxicities in Patients With Colorectal Cancer or Lung Cancer Receiving Cetuximab, Panitumumab, or Erlotinib Hydrochloride
SWOG Cancer Research Network
NCT01416688
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Dermatologic Complications records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Dermatologic Complications trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Dermatologic Complications page
2 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Dermatologic Complications trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- North Central Cancer Treatment Group sponsors the most Dermatologic Complications trials on record, review their full trial history before evaluating a specific study. See North Central Cancer Treatment Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Dermatologic Complications condition card totals 2 registered trials; most-linked intervention mometasone furoate; top US site state Illinois. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.